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Background: To investigate the association of DNA nucleotide excision repair (NER) defects with neurological
degeneration, cachexia and cancer, we performed autopsies on 4 adult xeroderma pigmentosum (XP) patients with
different clinical features and defects in NER complementation groups XP-A, XP-C or XP-D.
Results: The XP-A (XP12BE) and XP-D (XP18BE) patients exhibited progressive neurological deterioration with
sensorineural hearing loss. The clinical spectrum encompassed severe cachexia in the XP-A (XP12BE) patient,
numerous skin cancers in the XP-A and two XP-C (XP24BE and XP1BE) patients and only few skin cancers in the
XP-D patient. Two XP-C patients developed internal neoplasms including glioblastoma in XP24BE and uterine
adenocarcinoma in XP1BE. At autopsy, the brains of the 44 yr XP-A and the 45 yr XP-D patients were profoundly
atrophic and characterized microscopically by diffuse neuronal loss, myelin pallor and gliosis. Unlike the XP-A
patient, the XP-D patient had a thickened calvarium, and the brain showed vacuolization of the neuropil in the
cerebrum, cerebellum and brainstem, and patchy Purkinje cell loss. Axonal neuropathy and chronic denervation
atrophy of the skeletal muscles were observed in the XP-A patient, but not in the XP-D patient.
Conclusions: These clinical manifestations and autopsy findings indicate advanced involvement of the central and
peripheral nervous system. Despite similar defects in DNA repair, different clinicopathological phenotypes are seen
in the four cases, and therefore distinct patterns of neurodegeneration characterize XP-D, XP-A and XP-C patients.
Keywords: DNA damage, DNA repair, Neurodegeneration, Glioblastoma, CachexiaBackground
Xeroderma pigmentosum (XP) is a rare, inherited dis-
order of DNA repair characterized by sun sensitivity of
exposed tissues (skin, eye, oral mucous membranes) and
a greater than 10,000-fold increased risk of cutaneous,
ocular, and tongue neoplasms [1-4]. Some XP patients* Correspondence: kraemerk@nih.gov
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reproduction in any medium, provided the oralso have neurologic manifestations [3-11]. There are
seven DNA nucleotide excision repair (NER)-deficient
complementation groups designated XP-A through XP-
G and an XP variant form with defective trans-lesion
DNA polymerase eta [12,13]. Recently we reported on
106 XP patients seen at NIH over the past 4 decades [1].
Progressive neurologic degeneration was present in 24%
(25/106), primarily in XP-D (n=16) and XP-A (n=6) com-
plementation groups. Their core clinical features included
loss of intellectual function, abnormal speech, mutism,
areflexia, ataxia, peripheral neuropathy, and loss of the
ability to walk. Progressive sensorineural hearing loss wasThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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postmortem findings of XP, including involvement of
the nervous system, have been described in the litera-
ture [6,7,10,15-34]. Most of these patients were in com-
plementation group XP-A. There were no post-mortem
reports on XP-D patients.
Here we report the post-mortem findings in 4 XP
cases with different clinical features (Figure 1 and
Table 1). The XP-A and XP-D patients showed se-
vere progressive neurologic deterioration. The XP-A
and XP-C patients presented with hundreds of skin
cancers. The two XP-C patients died of internal neo-
plasms including glioblastoma in XP24BE and cer-
vical adenocarcinoma with tumor metastasis to
multiple organs and systems in XP1BE.Figure 1 XP patients studied. A and B: Case 1 XP-A patient (A) at age 17
and (B) at 37y with marked cachexia and thinning of subcutaneous tissues
face for removal of skin lesions. C: Case 2 XP-D patient at age 40y. She had
had only few pigmented lesions and skin cancers. D: Case 3 XP-C patient, a
skin and cheilitis. The patient underwent many surgical procedures for rem
28y (E) with multiple pigmented lesions, telangiectasia, cheilitis and cornea
for removal of skin cancers and at age 48y (F) following exenteration of boResults
Case histories
Case 1 (XP12BE - XP-A)
The patient was a 44 year-old female with XP who had
been followed at NIH since diagnosis at age 4 years
[4,8,9,14,26,35] (Figure 1A and B and Table 1). She experi-
enced the first acute sun-sensitivity reaction at age 3
months with erythema and swelling after minimal sun ex-
posure. Over time she developed freckle-like pigmentation
on the sun exposed skin of her face, neck and dorsal upper
extremities. Her first pathologically documented skin ma-
lignancy was a sclerosing basal cell carcinoma of the cheek
at age 8 years. Subsequently, the patient developed more
than two hundred skin cancers, which were mostly basal
cell carcinomas (BCC) with 1 squamous cell carcinomay with numerous freckle-like pigmented lesions on sun exposed skin
of face and chest. She had more that 100 surgical procedures on her
been well protected from sun exposure since early childhood and
t age 29y with multiple freckle-like pigmented lesion on sun exposed
oval of skin cancers on her face. E and F: Case 4 XP-C patient, at age
l clouding. Multiple surgical procedures were performed on her face
th orbits for treatment of ocular squamous cell carcinomas.
Table 1 Clinical and autopsy abnormalities in XP-A (XP12BE) and XP-D (XP18BE) patients compared to two XP-C patients
Case 1 Case 2 Case 3 Case 4
XP-A (XP12BE) (GM05509)* XP-D (XP18BE) (CRL1275)**(XPKABE) XP-C (XP24BE) (GM11638 XP-C (XP1BE) (GM10881)*
late onset juvenile form XP XP with neurological degeneration no neurological disease subclinical
neurodegeneration
Age at death/Gender/DOB d44 yr/F b1965 d45 yr/F b1964 d35 yr/F b1972 d49 yr/F b1944
XP complementation group XP-A XP-D XP-C XP-C
Mutations
(see text for details)
compound heterozygote compound heterozygote compound heterozygote homozygous
CLINICAL FINDINGS
Height 145.5 cm (<3 %ile) 165 cm (50–75 %ile) 153.3 cm - 34 yr (10 %ile 160 cm (25–50 %ile)
Weight 32 kg (<3 %ile) 60.6 kg (50 %ile) 56.7 kg - 35 yr (50 %ile) 76.6 kg (50–75 %ile)
Cachexia? yes no no no
Acute skin sunburning on
minimal exposure?
yes yes no no
Freckle-like skin lesions on
sun exposed skin?
yes yes yes yes
Skin cancer?1 >200 BCC and 1 SCC 7 SCC and 2 BCC >200 (190-BCC,3 SCC and 50 MIS) >200 (>35 BCC, >37 SCC, 2
soft tissue sarcoma, 28 MIS
and 6 Mel)
Microcephaly? yes (2%ile) no no no
Hearing progressive high frequency
sensorineural hearing loss
progressive high frequency sensorineural hearing loss normal subclinical high frequency
sensorineural hearing loss
at 48 yr
Deep tendon reflexes absent absent (1995) normal normal at 37 yr, ankle
hyporeflexia at 43 yr
Able to walk? no no yes yes
Able to talk? no no yes yes
Able to care for self? no no yes yes
Difficulty swallowing? yes - G-tube - age 37 yr yes - G-tube - age 44 yr normal normal
Primary ovarian failure? no unknown yes yes
Anterior eye abnormalities bilateral pinguecula, exposure
keratopathy2
bilateral pinguecula, exposure keratopathy2 corneal scar, pterygium blateral orbital
exenterations for infiltrative
SCC of globe3
Eye - retinal degeneration optic nerve atrophy2 no2 no unknown
Imaging of brain diffuse cerebral and cerebellar
atrophy (41 yr −2006)
minimal cortical atrophy (19 yr- 1983) left frontal lobe tumor slight cerebral cortical
atrophy and ventricular
enlargement (44 yr)
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Table 1 Clinical and autopsy abnormalities in XP-A (XP12BE) and XP-D (XP18BE) patients compared to two XP-C patients (Continued)
AUTOPSY FINDINGS
Thick calvarium? no yes; cortical sclerosis, no tumor seen no no
Brain weight [normal 1240
g (1050–1550)]
660g (~ 6mo) 760g (~1 yr) 1330g [normal] 1300g [normal]
Brain atrophy? yes - diffuse yes - diffuse no atrophy - tumor no, except optic nerves
secondary to orbital
exenteration
Dilated brain ventricles? yes yes asymmetric due to tumor no
Thin corpus callusum? yes yes no remarkable features no
Histological neuronal loss? yes - hippocampus, pons,
medulla, midbrain, thinned
cortex, small cerebellum
yes – outer cortex (neuronal loss and vacuolization
resembling status spongiosis), hippocampus (CA2 and
CA3 regions), basal ganglia, cerebellum
no remarkable features no
Histological gliosis? yes - midbrain, pons, medulla,
basal ganglia, thalamus,
hippocampus
yes - cortex, hippocampus no remarkable features yes - molecular layer of
cerebellum
Histological myelin pallor? yes - temporal lobe, frontal
lobe, cerebellum
yes - basal ganglia, cerebellum no remarkable features no remarkable features
Cerebellum Atrophy, loss of Purkinje cells
with axonal swelling,
Bergmann astrocytosis
atrophy, patchy Purkinje cell loss no remarkable features moderate to marked
Purkinje cell loss with
Bergmann astrocyte
proliferation
Dorsal root ganglia no remarkable features no remarkable features no remarkable features severe neuronal loss
Histology of peripheral
nerves
minimal focal perivascular
inflammation in the adjacent
connective tissue
no pathologic changes femoral nerve - unremarkable median nerve mild focal
interstital fibrosis, sural
nerve - no pathologic
diagnosis
EM of peripheral nerves axonal neuropathy not done not done not done
Eye pathology? neovascularization of cornea,
optic atrophy2
neovascularization of cornea, cataract2 not done sockets of orbits lined with
skin
Histology of muscles myofiber type -grouping no pathologic changes unremarkable angulated fibers of skeletal
muscles
Histology of Pharynx inflammation and fibrosis chronic inflammation normal normal
Esophagus no pathologic changes T-lymphocyte infiltration of Auerbach's plexus no pathologic changes no pathologic changes
Larynx no pathologic changes ulceration with chronic and acute inflammation pink mucosa delicate pink mucosa
Lungs normal bronchopneumonia bilateral pneumonia pulmonary emboli
Thyroid normal normal cystic nodule filled with pink, amprphous
material, consistent with goiter
follicular adenomas
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Table 1 Clinical and autopsy abnormalities in XP-A (XP12BE) and XP-D (XP18BE) patients compared to two XP-C patients (Continued)
Ovaries no pathologic changes no pathologic changes small - microscopic fibrosis, no follicles covered by tumor
Uterus leiomyomas adenomyosis small - calcified nodules 1 cm, leiomyomas covered by tumor
Breasts fibrocystic changes fibrocystic changes no masses no masses
Cause of death XP-related neurologic
degeneration
XP-related neurologic degeneration Glioblastoma WHO grade IV. Tumor cells
positive for GFAP and IDH1, negative for EGFR.
P53 positive in <5% tumor cells.
metastasis of well
differentiated mucinous
adenocarcinoma of uterine
endocervix
1BCC - basal cell carcinoma, SCC -squamous cell carcinoma, MIS - melanoma in situ 2From Ramkumar et al. (reference 26) 3From Gaasterland et al. (reference 48) *Coriell Institute for Medical Research cell culture
identification number **American Type Culture Collection cell culture identification number.
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http://www.actaneurocomms.org/1/1/4(SCC). At age 19 years, she was treated with oral 13-cis ret-
inoic acid for skin cancer prevention [36]. She responded
well with reduction in new skin cancer frequency from 43
BCC in two years before treatment to 3 new BCC after
two years of treatment. Eighteen months after the discon-
tinuation of 13-cis retinoic acid, she developed 18 new skin
cancers. In the following years, she practiced increased
protection from the sun with improved protective clothing
and sunblocking agents. She experienced progressive
neurologic decline, which further contributed to reduced
outdoor exposure. Over time, fewer skin cancers devel-
oped and her overall XP-related skin pigmentation faded
with only few lesions present.
While her early developmental milestones were within
normal range, neurological signs were noted at age 7 years,
with loss of deep tendon reflexes. At age 8 years, an audio-
gram revealed bilateral hearing loss at 8,000 Hertz, which
progressed over the years [9,14]. Learning difficulties and
an IQ of 79 were noted at age 15 yr. Computerized tomog-
raphy (CT) of the brain at age 20 showed no focal abnor-
malities and no appreciable atrophy (Figure 2A). At age 21
years, truncal ataxia became more prominent and tongue
movement appeared uncoordinated. At the age of 22, she
began to lose pain sensation, the Romberg test becameFigure 2 Case 1. XP-A A: Two consecutive Computed Tomography (CT) im
abnormalities and no appreciable brain atrophy. B: Two axial T1-weighted
obtained at age 41y. There is evidence of prominent brain atrophy manifes
subarachnoid spaces. C: Gross atrophy of the right brain hemisphere (right
same age and gender (left). Loss of brain substance appears to be greater
(H&E, x 40). E: Luxol fast blue stain of the right temporal lobe showing patcpositive and she exhibited child-like behavior [9]. By age 37
years, she was immobile and required assistance to walk.
Because she was unable to swallow solid food without
choking a gastrostomy tube (G-tube) was placed for nutri-
tional support. Despite this therapeutic measure, she con-
tinued to become markedly cachectic. At age 41 years,
there was evidence of prominent brain atrophy on imaging
studies (Figure 2B). Neurological deterioration progressed
inexorably and she became completely unresponsive and
expired at the age of 44. An unrestricted autopsy was
performed. Compound heterozygous mutations were de-
tected in the XPA DNA repair gene (Table 1) with G>T
intron 3 splice acceptor, and G>C splice donor of exon 4
[37,38]. The post-UV DNA repair rate (unscheduled DNA
synthesis (UDS)) of the cultured skin fibroblasts was about
1% of normal [4,35,39,40]. Post-UV survival of cultured
skin fibroblasts was markedly reduced [41].
Case 2 (XP18BE- XP-D)
This 45-year-old female patient with XP had a history of
progressive neurologic deficits [14,26] (Figure 1C and
Table 1). She presented to the NIH at age 5 years with
hearing difficulty and developmental delay. In addition,
she had marked photosensitivity with blistering onages of the brain obtained at age 20y. There are no focal brain
Magnetic Resonance Images (MRI) of the brain in the same patient
ted by enlargement of the ventricles and widening of the intracranial
, comparable image to 2B) in comparison to the normal brain at the
in the white matter. D: Thinning of cortex of the right temporal lobe
hy loss of myelination.
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http://www.actaneurocomms.org/1/1/4minimal sun exposure. At age 8 years, SCC was removed
from her nose. Subsequently, she practiced extensive
early sun protection and only developed 9 skin cancers
during her lifetime (2 BCC and 7 SCC). At age 13 years,
she was first noted to have high frequency sensorineural
hearing loss and at age 30 years, a repeat audiologic
evaluation revealed profound sensorineural hearing loss
[14]. At age 31 she developed ataxia with a broad-based
gait, eventually requiring confinement to a wheelchair at
age 36. By age 39 years, she was unable to care for her-
self and needed to read lips and write notes in order to
communicate. She developed progressive dysphagia and
at age 44 years a gastrostomy tube was placed for nutri-
tional support that proved successful for weight main-
tenance. Her final admission was for pneumonia and
sepsis. She expired 3 days later and an unrestricted aut-
opsy was performed. Laboratory testing demonstrated
XP-D complementation group (Table 1) with compound
heterozygous mutations in the XPD (ERCC2) gene:
R616P and R683W. Cultured skin fibroblasts (XPKABE)
showed post-UV UDS of 25-50% of normal but mark-
edly reduced post-UV survival [41].
Case 3 (XP24BE- XP-C)
Case 3 was a 35-year-old female diagnosed with XP at
age 6 years (Figures 1D and 3 and Table 1). During her
disease course, she developed almost 200 skin cancers
including BCC, SCC, 11 melanomas in situ (Figure 3G
and H), and one invasive melanoma (0.65 mm). At age
11 years, she participated in a study with oral 13-cis ret-
inoic acid (isotretinoin) for skin cancer chemoprevention
with a good response [36]. She developed premature
menopause before age 30 years.
At age 29 years, she was found to have an asymptom-
atic left frontal lobe, non-enhancing brain mass lesion
(Figure 3A). The patient elected follow-up with serial
MRIs. However, two years later, the lesion enlarged and
became symptomatic. She underwent craniotomy with
subtotal resection of the mass. Pathologic examination
revealed a low grade astrocytoma (Figure 3C and D).
She was treated postoperatively with external beam radi-
ation therapy with a total dose of 5,940 cGy. As with
other XP patients receiving radiotherapy [42], she had a
normal skin response. The patient was stable until age of
34 years, when she developed expressive aphasia and fa-
tigue. Imaging revealed recurrent tumor with abnormal
increase of enhancement on the post-contrast scan
(Figure 3B), a feature considered indicative of malignant
transformation. Resection showed that the tumor had
progressed to glioblastoma (Figure 3E and F). Worsening
aphasia and right-sided hemiparesis complicated her post-
operative course. She began temozolomide therapy. She
did not have any unusual side effects to standard doses of
temozolomide which was well tolerated. The patient’scondition continued to deteriorate, and she expired at
home. A partially restricted autopsy was performed. La-
boratory testing showed compound heterozygous muta-
tions in the XPC gene (Table 1): A155X and 83bp
insertion of intron 5.1 with stop codon 34 codons down-
stream [43].Case 4 (XP1BE- XP-C)
Case 4 was a 49-year-old Caucasian female with XP,
who had been followed at the NIH since age 24 years
[4,10,14,44,45] (Figure 1E and F and Table 1). She had
more than 200 biopsy-proven BCC and SCC and devel-
oped approximately 38 separate primary melanomas,
half of which were in-situ lesions [46]. A number
of these lesions responded to intra-lesional alpha
interferon [47]. Bilateral orbital exenterations were
performed for recurrent squamous cell carcinomas of
the cornea and globe at age 32 and 36 years, followed
by 5,000 rads of irradiation with a normal response
[48]. In addition, she was found to have subclinical,
asymptomatic neurologic disease, including right
peroneal nerve weakness and subclinical hearing loss,
without mental deterioration [10,14,44]. She had
multiple urinary tract infections, chronic glomerulo-
nephritis following left nephrectomy at age 40 years for
staghorn calculi, premature menopause secondary to
hypogonadotropic hypogonadism, and fatty liver. Just
prior to death, she experienced shortness of breath and
developed a superaventricular tachycardia. An unre-
stricted autopsy was performed [10]. She had mutations
in the XPC gene (Table 1): homozygous deletion of AA
Exon 8 del AA 1396–7, fs188 - stop 5 codons down-
stream [49]. Cultured skin fibroblasts had about 10% of
normal post-UV UDS [4,35,39]. Post-UV skin fibroblast
cell survival was reduced [41].Pathological examinations
Case 1 (XP12BE- XP-A)
Neuropathology
Gross description: The brain weighed 660 g (normal
for ~ 6 month old infant) and was bisected fresh (Figure 2C
and Table 1). The leptomeninges were smooth and trans-
parent. There was no venous congestion or evidence of
acute subarachnoid hemorrhage. Generalized brain atrophy
with marked dilatation of lateral ventricles and thinning of
the corpus callosum was noted. The gyri/sulci were grossly
within normal limits. Examination of the basal cerebral vas-
culature revealed no dilatation, thrombosis, atheroma, or
other abnormalities. Coronal sectioning of the right cere-
bral hemispheres confirmed diffuse atrophy (Figure 2C)
with marked ventricular dilatation. While the cortical rib-
bon was thin throughout the hemispheres, the loss of brain
substance seemed greater in the subjacent white matter.
Figure 3 Case 3. XP-C A-B: MRI images of brain tumor. A: Axial post contrast T1-weighted MRI image of the brain obtained at age 29y showing
a space occupying lesion in the left frontal lobe. The lesion demonstrates decrease signal intensity and does not enhance. The lack of
enhancement after contrast indicates low histologic grade of this tumor. B: Axial post contrast T1-weighted MRI image of the brain in the same
patient obtained five years later. There is evidence of tumor recurrence after surgery. The tumor demonstrates abnormal increased enhancement
on the post contrast scan. This feature is indicative of malignant transformation. C: Histologic features of the primary tumor (as shown in A),
a low grade astrocytoma (inset shows slightly atypical cells). D: Histologic features of the recurrent tumor, a glioblastoma. The tumor is characterized by
increased cellularity, and pseudo-palisading necrosis (arrow), multinucleated tumor cell is shown in inset. E: Immunohistochemistry shows that the
tumor cells are positive for IDH1 (X200). F: Pigmented lesion showing irregular size, shape and color. G: Histology of F showing melanoma in situ (x400).
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subthalamic nuclei, basal ganglia, and the hippocampus
were grossly unremarkable. Serial sectioning of the right
brainstem and cerebellum revealed no grossly significant
abnormalities. The spinal leptomeninges were thin and
translucent and the subarachnoid space was free of exu-
dates. The spinal arteries and veins were unremarkable. Sig-
nificant eye findings included exposure keratopathy and
bilateral optic atrophy as previously described [26].
Microscopic description of sections from the midbrain,
pons, medulla and hippocampus revealed neuronal loss and
gliosis. In addition increased capillary density was seen in
the thalamus. Sections from the right frontal and temporal
cortex (Figure 2D) showed neuronal loss and gliosis accom-
panied by microglial activation. In addition, patchy white
matter rarefaction was seen and highlighted by a LFB stain
(Figure 2E). There were no neuritic plaques, tangles or
neuronal inclusions. Sections from the right cerebellum
demonstrated overall atrophy of the folia. Focal loss of
Purkinje cells with increased numbers of torpedoes
(Purkinje cell axonal swellings) and associated Bergmann
astrocytosis was seen at the junction of the granular and
molecular layers. The granular layer was mostly preserved
with only mild rarefaction. A section from the dura was un-
remarkable. Electron microscopy of the radial nerve showed
increased interstitial collagen with reduced density of large
and myelinated fibers, axonal atrophy and occasional re-
generation clusters consistent with axonal neuropathy
(Figure 4A). Rare thinly myelinated fibers were seen. De-
nervation atrophy (esterase positive angular atrophic fibers,
pyknotic nuclear clumps) of the skeletal muscles was
present. Fiber type grouping, however, was not a feature.
Temporal bone histology revealed marked atrophy of the
cochlear sensory epithelium and neurons [14].
Other findings: The indicated cause of death was XP-
related neurologic degeneration. Hemangioma of the lip,
seborrheic keratosis, uterine leiomyoma and fibrocystic
change in bilateral breasts were also identified (Table 1).Figure 4 Case 1. XP-A Axonal neuropathy and denervation atrophy of ske
reduction in the number of large myelinated axons accompanied by increa
with axonal neuropathy. B: Skeletal muscle showing marked variation in fib
clumps, fibrosis with fat replacement.Case 2 (XP18BE- XP-D)
Neuropathology
Gross description of the skull was notable for a substan-
tially thickened calvarium, measuring 2.3 cm (frontal)
(Figure 5A), 1.7 cm (occipital) and 1.0 cm (temporal).
There were two boney excrescences measuring 1.4x1.2x
0.4 cm and 1.2x1.0x0.6 cm in the right middle fossa of
the skull base. The brain weighed 760 g (normal for ~ 1
yr old child) and showed diffuse widening of the sulci
consistent with global atrophy (Table 1). The cerebral
gyri/sulci were unremarkable and the hemispheres were
symmetric. Coronal sections of the hemispheres con-
firmed the diffuse cerebral atrophy with dilated ventricles
and a thin corpus callosum, but no focal lesions were
seen (Figure 5B). Cerebellar hemispheres and vermis also
appeared atrophic. Examination of peripheral nerves in-
cluding both brachial plexuses, and radial, median, ulnar,
femoral, sural and vagal nerves was unremarkable.
Microscopic description: Sections from the right fron-
tal and parietal cortex showed thinning of the cortical
ribbon with extensive neuronal loss widespread vacuol-
ization of the neuropil (Figure 5C and 5D). Vacuolization
was most prominent in the deep cortical layers (resem-
bling the pattern of coarse vacuolation termed status
spongiosis); neuronal loss and gliosis were accompanying
features. Neurofibrillary tangles, plaques or other inclu-
sions or storage products were not identified. Sections
from the hippocampus demonstrated atrophy, gliosis,
and pyramidal cell loss and vacuolization of the neuropil.
Hippocampal neuronal loss most prominently involved
the CA2 and CA3 sectors. Sections from the right basal
ganglia and mid brain-pontine junction revealed exten-
sive neuronal loss and gliosis, Figure 6 (A-C). Sections
from the right cerebellum showed focal loss of Purkinje
cells and accompanying Bergmann gliosis (Figure 5E and
5F) with patchy myelin pallor of the cerebellar white
matter (Figure 5G). A section from the grossly described
boney excrescence in the right middle fossa showedletal muscle. A: Electron microscopy showing mild to moderate
sed collagen and axonal degeneration and axonal atrophy consistent
er size, with rounded and angulated atrophic fibers, pyknotic nuclear
Figure 5 Case 2 XP-D Neuropathologic changes. A: Thick calvarium (2.3 cm, frontal). B: Global cerebral atrophy with dilated ventricles and
thinned corpus callosum. C-D: Thinning of the cortical ribbon with vacuolization of the neuropil, neuronal loss and gliosis in the right frontal (C,
x100) and parietal cortex (D, x200). E-F: Patchy loss of Purkinje cells in the right cerebellum with Bergman gliosis and axonal torpedos (E, x40; F,
x200). G: Patchy myelin pallor in the right cerebellum (x100). H: GFAP highlights the reactive astrocytes in parietal lobe (x200).
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tochemistry and special stains for GFAP and LFB were
performed on sections from the cortex, hippocampus and
cerebellum. The GFAP stain highlighted reactive astro-
cytes (Figure 5H).
Histology of the peripheral nerves (Figure 7A and 7B),
pharyngeal muscle and esophageal muscle were unre-
markable. Examination of the esophagus showed infiltra-
tion of the ganglia of Auerbach’s plexus by CD3 positive
T-lymphocytes (Figure 7C and 7D).
Other findings: The immediate cause of death was aspir-
ation pneumonia. Focal patchy consolidation, bronchialmucus plugging and a cluster of plant (vegetable) cells
with alveolar and interstitial infiltration by neutrophils
and lymphocytes were seen in both lungs. A small
(0.2 cm), hemangioma was present on the patient’s
back. Laryngeal ulceration, bilateral breast fibrocystic
changes, mild renal glomerulosclerosis, subserosal uter-
ine adenomyosis, and cholelithisasis were also present
(Table 1). There was no ocular neoplasm identified.
The eye findings were reported previously [26], and
consisted of bilateral pinguecula, corneal pannus,
exposure keratopathy, retinal gliosis and bilateral per-
ipheral retinal pigmentary degeneration.
Figure 6 Case 2 XP-D. Hippocampal sections showed neuronal loss involving CA2/CA3 sectors (A, X200); Neuropil disorganization seen in basal
ganglia (B, X200) and midbrain-pontine areas (C, X200).
Lai et al. Acta Neuropathologica Communications 2013, 1:4 Page 11 of 17
http://www.actaneurocomms.org/1/1/4Case 3 (XP24BE- XP-C)
Neuropathology
Gross findings: There were several metal plates on the
frontal bone indicating prior surgery. The cranial vault
appeared of normal thickness. The brain weighed 1330 g
fresh (normal for adult) (Table 1). The leptomeninges over
the left frontal region were slightly distorted with multiple
sutures; the leptomeninges over the right hemisphere were
unremarkable. The entire brain appeared edematous and
the left cerebral hemisphere was enlarged, and with midline
shift, but no obvious herniations were identified. Examin-
ation of the arteries of the circle of Willis and their major
branches revealed no evidence of atherosclerosis, thrombus
formation or malformations. The superficial veins and cra-
nial nerves were unremarkable. Coronal sectioning of the
cerebral hemispheres revealed an ill-defined tumor massFigure 7 Case 2 XP-D. Neuropathologic changes. A and B, No specific ab
(A, x100) and LFB/PAS (B, x100). C and D, Periganglial lymphocytic infiltratiinfiltrating the left frontal and temporal lobes, crossing the
corpus callosum and invading the right cerebral hemi-
sphere. The tumor was tan/white, soft with grey gelatinous
areas, resembling tumor necrosis. Serial transverse section-
ing of the brain stem and cerebellum revealed no abnor-
malities. The spinal cord was grossly unremarkable.
Microscopic findings: The prior primary tumor as shown
in Figure 3A was a low grade astrocytoma (Figure 3C)
with only slightly pleomorphic tumor cells (Figure 3C
inset) that stained positive with GFAP. The proliferative
index of the tumor cells was low as indicated by the MIB-1
staining. At autopsy, the diffusely infiltrative astrocytic
tumor showed high- grade features characterized by fre-
quent mitotic figures, microvascular proliferation, and
pseudopalisading necrosis (Figure 3D). Scattered
multinucleated tumor cells were seen (Figure 3D inset).normality was appreciated in peripheral nerve stained with H&E
on of Auerbach’s plexus in the esophagus (C, x40; D, x 200).
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(Figure 3E), and were negative for EGFR. MIB-1 stain indi-
cated a high proliferative rate and p53 stain showed focal
positivity in less than 5% of tumor cells. The sections from
the remaining brain and spinal cord did not show signifi-
cant pathologic changes.
Other findings included bilateral pneumonia with bac-
terial and fungal infection, which was the immediate
cause of her death (Table 1). The ovaries were small with
microscopic fibrosis with no follicles observed. A cutane-
ous melanoma in situ (Figure 3F and 3G) and a basal cell
carcinoma were identified a few weeks before the patient
expired. Several pigmented skin lesions were sampled at
autopsy, including lentiginous melanocytic proliferation,
atypical melanocytic proliferation, severely atypical mela-
nocytic proliferation and seborrheic keratosis. No other
skin cancers were identified.Case 4 (XP1BE- XP-C)
Neuropathology
Gross description: The brain weighed 1300 gm (normal for
an adult) (Table 1) and was bisected fresh. The dura, cere-
bral hemispheres, and infratentorial structures were exter-
nally unremarkable. The optic nerves and chiasm were
atrophic. There was patchy non-occlusive atherosclerosis
involving the basilar artery and circle of Willis. Sequential
sections through the hemispheres, brain stem, and cere-
bellum revealed no focal lesions. The spinal arteries and
veins were unremarkable. Peripheral nerves includingFigure 8 Case 4 XP-C Neuropathologic changes. A: The cerebellum sho
geniculate nuclei reveal degenerative changes, including axonal loss, gliosi
bilateral orbital exenterations (B. H&E x200; C. immunostain for Bielschowsk
ganglia show severe neuronal loss and accompanying fibrosis (H&E, x200).median, sural nerves and celiac plexus revealed no gross
abnormalities.
Microscopic description: The cerebellum showed focal
loss of Purkinje cells (Figure 8A) with accompanying
Bergmann astrocyte proliferation, and gliosis of the mo-
lecular layer. The hemispheric cortical grey matter and
subcortical white matter were unremarkable. The pituit-
ary was unremarkable. Sections of optic nerves and gen-
iculate nuclei revealed degenerative changes (Figure 8B
and 8C) including marked axonal loss with gliosis and
resultant fibrosis of the fibro-vascular bundles and trans-
synaptic degeneration in the lateral geniculate body with
gliosis, consistent with the patient’s 10-year history of bilat-
eral orbital exenterations [48]. Sections of spinal cord re-
vealed no pathologic changes; however, the dorsal root
ganglia showed severe neuronal loss with sclerotic foci oc-
cupying previous neuronal sites (Figure 8D) as reported pre-
viously [10]. Peripheral ganglia (celiac) were unremarkable.
Multiple pulmonary emboli were the immediate cause
of her death. The underlying cause of the pulmonary em-
boli was a clinically unsuspected well differentiated mucin-
ous adenocarcinoma of endocervical origin (Figure 9A),
which directly invaded the surrounding pelvic organs in-
cluding ovaries and sigmoid colon, causing diffuse abdom-
inal carcinomatosis that involved the diaphragm
(Figure 9B), omentum, appendix, large and small bowel,
and metastasized to multiple splenic hilar lymph nodes,
spleen and lungs.
Other findings included obesity, glomerulonephritis, mul-
tiple simple renal parenchymal cysts, steatohepatitis, nodularws focal loss of Purkinje cells (x100). B-E: Sections of optic nerves and
s, and fibrosis (arrows) in keeping with the patient’s 10 year history of
y, x200 D. Masson stain, x200, E. LFB/PAS stain, x200). F. Dorsal root
Figure 9 Case 4 XP-C Carcinomatosis. Well differentiated mucinous adenocarcinoma of endocervical origin (A, x200), caused extensive
abdominal carcinomatosis and involved diaphragm (B, x200).
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and left ventricular hypertrophy, and thyroid follicular aden-
omas. In addition, there was mild to moderate atheroscler-
osis of the left anterior descending artery, and moderate to
severe atherosclerosis of the right coronary artery.
Discussion
Neurodegeneration in XP patients
The present study represents the first detailed description
of the postmortem neuropathologic findings in an XP-D
patient. These features have been systematically compared
to an XP-A and two XP-C patients (Table 1). Of note, all
four patients were included in a large series of XP patients
followed at the NIH for many years permitting close ob-
servation of disease progression and the effects of treat-
ment [1,14]. Major clinical neurologic abnormalities in
XP patients include sensorineural hearing loss, peripheral
neuropathy, microcephaly and dementia. The XP-A and
XP-D patients were diagnosed with XP at age 4 and 5
years, respectively, and developed high frequency sensori-
neural hearing loss at a young age. Their neurologic status
showed progressive decline with loss of ability to walk and
talk leading to inability to care for themselves and death at
age 44 and 45 years of age (Table 1).
The core neuropathologic findings of this study are pro-
found global cerebral and pancerebellar atrophy in the
XP-A and XP-D cases. The most striking gross finding
was generalized brain atrophy (660 and 760 g) with brain
size similar to that of a 6 to 12 month old infant [50]. Con-
sistent with what has been described previously in XP-A
patients [4-6,11], we found brain atrophy involving all
lobes. There was diffuse neurodegeneration with neuronal
loss and gliosis of both hemispheres, similar changes in
the cerebellum, basal ganglia, and corticospinal tracts. Ret-
inal gliosis was identified in both cases [26]. In addition,
the XP-D patient had a thickened calvarium, vacuolization
of the deep cortical neuropil, patchy Purkinje cell loss, and
infiltration of the ganglia of esophageal Auerbach’s plexus
by T-lymphocytes. Intriguingly, calvarial thickening which
has been described in XP-A patients from Finland [5] was
not observed in the XP-A patient.Both XP-A and XP-D patients developed dysphagia,
which poses difficult challenges for clinical management.
In addition to CNS dysfunction, we carefully evaluated
the peripheral neuromuscular system, and found axonal
neuropathy and chronic denervation atrophy of skeletal
muscle including those that related to swallowing in the
XP-A patient. The peripheral neuropathy has been pre-
viously reported and involves both motor and sensory
nerves. The underlying pathogenic mechanism is thought
to be a neuronopathy [7,51]. In contrast, significant per-
ipheral neuronopathy was not identified in the XP-D pa-
tient where section of the esophagus showed T-cell
infiltrates of Auerbach’s plexus. This finding suggests an
immune-mediated mechanism may be associated with
acute autonomic and sensory neuropathy leading to im-
pairment of both superficial and deep sensation in the
XP-D patient.
Both the XP-A and the XP-D patients had severe pro-
gressive neurodegeneration. However, while the swallowing
difficulty led to the placement of a G-tube for feeding of
both patients, only the XP-A patient developed cachexia.
The XP-D patient retained her weight, which suggests that
cachexia is not directly related to the extent of neuro-
degeneration or the inability to swallow.
A patient with XP/Cockayne syndrome complex was
described with a defect in the XP-G gene (XP20BE) [27].
He died at age 6 yr and had marked growth retardation
with short stature and severe cachexia. However the aut-
opsy findings of XP20BE were different from the XP-A
and XP-D cases. His brain appeared proportionally small
and not atrophic with a grossly normal cortical ribbon
and an unusual tigroid pattern of demyelination. In
addition, the patient had cataracts, and retinal pigmen-
tary atrophy typical of Cockayne syndrome.
With respect to the two XP-C cases, one case showed un-
expected carcinomatosis with endocervical adenocarcinoma.
The other patient developed a glioblastoma, which arose
from a pre-existing low-grade, diffuse astrocytoma. This ob-
servation is furthered supported by the IDH1 labeling of the
tumor cells. It has been reported that as high as 90% of dif-
fuse and anaplastic gliomas and secondary glioblastomas
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IDH1-positive [52]. The generalized neurodegenerative
changes seen in the XP-A and XP-D cases were not ob-
served in the XP-C cases although the older patient had
focal loss of Purkinje cells and, neuronal loss in the dor-
sal root ganglion.
There was a clinical correlation between the skin ab-
normalities and the presence of progressive neurological
degeneration. In a longitudinal study of 73 XP patients
with audiograms examined at the NIH, all 17 patients
who developed sensorineural hearing loss and progres-
sive neurological degeneration had a history of acute
burning on minimal sun exposure, including the XP-A
and XP-D patients in this report [14]. This burning his-
tory was not present in the XP-C patients and they did
not show progressive neurological degeneration. Further,
cultured skin cells from XP patients with a history of
burning on minimal sun exposure and neurological de-
generation were hypersensitive to killing by ultraviolet
radiation [41,53].
Cancer in XP patients
Our previous data have shown that 65% (69/106) of XP
patients developed sunlight-induced skin cancers. Non-
melanoma skin cancer was increased 10,000-fold and
melanoma was increased 2,000-fold in patients under
age 20 [1,2]. The XP-A, and XP-C patients developed
hundreds of skin cancers (Table 1). The XP-A patient
and XP-C patient XP24BE were treated with oral 13-cis-
retinoic acid for chemoprevention of skin cancer [36].
They both had a good response, with no further skin
malignancies identified at autopsy. The XP-D patient
was sun protected from early childhood and developed
only 9 skin cancers.
The XP-C patients developed internal cancers with a gli-
oma in XP24BE and a cervical adenocarcinoma in XP1BE.
XP patients have been estimated to have an 11-fold in-
crease in internal neoplasms and a 50-fold increase in can-
cers of the central nervous system [2]. The reported
tumors include Schwannoma in a 73 y/o [1], spinal cord
astrocytoma in a 24 y/o, gastric cancer in a 50 y/o and
lung cancer in a 37 y/o smoker [42]. Some carcinogenic
components of cigarette smoke bind to DNA forming ad-
ducts that are repaired by the NER system. It is thought
that the lung cancers in the young XP patients are related
to mutations resulting from this unrepaired damage. The
underlying mechanism of induction of the CNS neoplasms
is not known.
DNA repair defects in XP patients
Defects in the repair-enzyme genes XPA through XPG
are known to cause XP [12,13,54]. Cells from XP pa-
tients with mutations in the XPC DNA repair gene have
defective global genome DNA repair and normaltranscription coupled repair. In contrast, cells from pa-
tients with mutations in the CSA or CSB genes have de-
fects only in transcription coupled repair. These patients
have clinical Cockayne syndrome with severe progressive
neurological degeneration with short stature and retinal
degeneration but without an increase in cancer [12,54].
However, cells from XP patients with mutations in the
XPA and XPD genes have defective global genome repair
and in addition, defective transcription coupled DNA re-
pair. This additional transcription coupled DNA repair
defect is associated with progressive neurological degen-
eration in humans (see for example [5]) and in mouse
model systems [55]. Patients with trichothiodystrophy
have mutations in the XPD gene in association with de-
velopmental abnormalities (including absent myelin in
the brain) as well as sulfur deficient brittle hair, cata-
racts, bone abnormalities and increased susceptibility to
infections, but no increase in cancer [12,54,56]. The level
of DNA repair does not correlate with the clinical
phenotype. Thus, while cells from XP-A patients with
severe neurological degeneration generally have <2% of
normal post-UV unscheduled DNA synthesis (UDS) in
cultured skin fibroblasts, cells from XP-D patients, who
also have severe neurological degeneration, have 25-50%
UDS and cells from Cockayne syndrome patients have
normal UDS. Further, cells from XP-C patients with no
neurological abnormalities have 10% UDS [4,35,39,41,56].
Thus the relationship of mutations in the DNA repair
genes to clinical phenotypes is complex and the precise
mechanisms of these differences are not understood.
XP patients have defective repair of UV induced DNA
damage to skin and eyes. Unrepaired DNA damage can
lead to increased cell death and to a high frequency of
somatic mutations in the surviving, dividing cells. This
process is believed to underlie the skin sun sensitivity
and high frequency of sunlight-induced cancers in XP
patients. Skin tumors from XP patients frequently have
evidence of UV type mutations [57,58]. There is a good
correlation between post-UV killing and neurological de-
generation in cultured cells from XP patients. Thus, skin
fibroblasts from XP-A and XP-D patients with severe
neurological degeneration are more sensitive to post-UV
killing than are cells from XP-C patients who have no
neurological abnormalities [41]. However, UV radiation
does not reach the brain because of shielding from the
scalp and bones of the skull. It has been hypothesized that
oxidative DNA damage generated through metabolism or
other sources might produce DNA damage that is not
repaired in the non-dividing cells of the nervous system
leading to progressive neuronal death [8]. Most types of
oxidative DNA damage are repaired by base excision re-
pair, a process that is not defective in XP cells. Indeed, both
XP-C patients received therapeutic doses of x-radiation
(which produces oxidative damage) for treatment (brain
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spinal cord astrocytoma in another XP-C patient [42])
(Table 1) with a normal response. However, certain types
of products of oxidative DNA damage, such as cyclo-
purine deoxynucleosides, are repaired by the NER system.
Impaired repair of this type of oxidative DNA damage
has been proposed as a mechanism of the progressive
neurodegeneration seen in these XP patients [59,60].
Conclusions
In conclusion, while all 4 XP patients had defects in NER
genes, they had markedly different phenotypes with differ-
ent clinical consequences. Three of the patients had hun-
dreds of skin cancers early in life, and oral therapy with
retinoids and increased sun protection proved effective in
2 of them. None of these XP patients died from their skin
cancers. Two died from internal neoplasms (glioblastoma
and endocervical adenocarcinoma) and the other two
adult patients died from progressive neurodegeneration.
Understanding the complex relationships of these DNA
repair defects to these causes of death are a challenge for
future investigations.
Methods
Neuropathological examination
The patients were examined at the NIH under protocols
approved by the Institutional Review Board of the National
Cancer Institute. They gave their permission for use of
identifying images. The families of the patients have given
their consent for performance of the autopsies. The brain,
peripheral nerves, muscles were fixed with 10% buffered
formalin and embedded in paraffin. Histological examina-
tions were performed on 5 μm thick sections using
hematoxylin–eosin (HE). Selected sections were evaluated
with special stains (luxol fast blue (LFB), Bielschowsky,
Masson’s trichrome) and immunostains (glial fibrillary
acidic protein (GFAP), synaptophysin, NeuN, neurofilament
proteins, KP-1, beta-amyloid, Isocitrate dehydrogenase 1
(IDH1), p53, EGFR, MIB-1). For immunohistochemical
analyses, 5 μm thick sections were serially cut in selected
brain regions and brain tumors. The control subjects had
no neurological abnormalities and showed no morpho-
logical changes in the brain. Slides were incubated in
Tris with 3% goat serum for 15 min and then incubated
for 1–2 h at room temperature with primary antibody.
Detection was carried out using an automated slide stainer
(DAKO; Autostainer) with a horseradish peroxidase/3,30-
diaminobenzidine polymer-based detection system (DAKO;
Envision+). No staining was observed in the sections incu-
bated in the absence of either antibody.
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